Bank of New York Mellon Corp Has $5.72 Million Stake in Arena Pharmaceuticals, Inc. (ARNA)

Bank of New York Mellon Corp decreased its stake in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 1.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 168,537 shares of the biopharmaceutical company’s stock after selling 1,799 shares during the period. Bank of New York Mellon Corp owned 0.43% of Arena Pharmaceuticals worth $5,724,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new position in shares of Arena Pharmaceuticals during the 3rd quarter valued at about $9,973,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Arena Pharmaceuticals by 16.6% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 209,085 shares of the biopharmaceutical company’s stock valued at $7,103,000 after acquiring an additional 29,732 shares during the last quarter. Pura Vida Investments LLC increased its holdings in shares of Arena Pharmaceuticals by 219.1% during the 3rd quarter. Pura Vida Investments LLC now owns 111,700 shares of the biopharmaceutical company’s stock valued at $2,848,000 after acquiring an additional 76,700 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Arena Pharmaceuticals by 38.6% during the 4th quarter. American Century Companies Inc. now owns 90,102 shares of the biopharmaceutical company’s stock valued at $3,061,000 after acquiring an additional 25,108 shares during the last quarter. Finally, Bailard Inc. acquired a new position in shares of Arena Pharmaceuticals during the 4th quarter valued at about $2,752,000. 73.05% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

A number of research analysts have recently commented on the company. BidaskClub lowered Arena Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Citigroup reissued a “buy” rating and set a $62.00 price objective on shares of Arena Pharmaceuticals in a report on Wednesday, March 21st. Wells Fargo upgraded Arena Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Wednesday, January 3rd. Zacks Investment Research upgraded Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Finally, Needham & Company LLC upgraded Arena Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $30.89 to $60.00 in a research note on Tuesday, March 20th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $52.25.

Shares of NASDAQ:ARNA opened at $33.88 on Friday. Arena Pharmaceuticals, Inc. has a twelve month low of $11.30 and a twelve month high of $45.85. The company has a market cap of $1,780.31, a P/E ratio of -12.88 and a beta of 1.49. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.28.

Arena Pharmaceuticals (NASDAQ:ARNA) last announced its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.30. Arena Pharmaceuticals had a negative return on equity of 62.82% and a negative net margin of 250.93%. The firm had revenue of $15.40 million during the quarter, compared to the consensus estimate of $5.75 million. During the same quarter in the prior year, the company earned $1.60 EPS. The firm’s revenue for the quarter was down 77.8% compared to the same quarter last year. equities research analysts forecast that Arena Pharmaceuticals, Inc. will post -2.74 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3337152/bank-of-new-york-mellon-corp-has-5-72-million-stake-in-arena-pharmaceuticals-inc-arna.html.

Arena Pharmaceuticals Company Profile

Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Want to see what other hedge funds are holding ARNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).

Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Dairy Crest  Receives GBX 610 Consensus PT from Analysts
Dairy Crest Receives GBX 610 Consensus PT from Analysts
Brokerages Set NXP Semiconductors  Target Price at $120.50
Brokerages Set NXP Semiconductors Target Price at $120.50
Sientra’s  “Buy” Rating Reiterated at Canaccord Genuity
Sientra’s “Buy” Rating Reiterated at Canaccord Genuity
Sleep Number  Price Target Lowered to $25.00 at Bank of America
Sleep Number Price Target Lowered to $25.00 at Bank of America
ValuEngine Lowers Carrols Restaurant Group  to Sell
ValuEngine Lowers Carrols Restaurant Group to Sell
Synchronoss Technologies  Stock Rating Upgraded by BidaskClub
Synchronoss Technologies Stock Rating Upgraded by BidaskClub


© 2006-2018 Ticker Report. Google+.